Chijioke Nze, M.D., M.P.H
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Harvard Medical School, Boston, Massachusetts, US, MD |
| 2016 | Harvard School of Public Health, Boston, Massachusetts, US, M.S. in Master of Public Health – Health Policy |
| 2012 | University of California Santa Barbara, Santa Barbara, California, US, BS in Bachelors in Science, Biochemistry |
Postgraduate Training
| 2020-2023 | Clinical Fellowship, Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2020 | Clinical Residency, Internal Medicine Residency, Brigham and Women’s Hospital, Boston, Massachusetts |
Licenses & Certifications
| 2024 | Georgia Composite Medical Board |
| 2024 | Florida Board of Medicine |
| 2024 | Arizona Board of Medical Examiners |
| 2024 | Tennessee Board of Medical Examiners |
| 2024 | Louisiana State Board of Medical Examiners |
| 2024 | Washington State Department of Health |
| 2024 | Alabama Board of Medical Examiners |
| 2024 | Mississippi State Board of Medical Licensure |
| 2024 | Oklahoma State Board of Medical Licensure |
| 2023 | American Board of Internal Medicine- Hematology |
| 2023 | Drug Enforcement Administration |
| 2023 | American Board of Internal Medicine- Medical Oncology |
| 2022 | Texas Medical License |
| 2021 | American Board of Internal Medicine- Internal Medicine |
Experience & Service
Intramural Institutional Committee Activities
Member, CPRIT Clinical Trial Network Steering Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Cancer Survivorship Research Advisory Workgroup, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2027
Member- Reviewer, Lymphoma Outcomes and Translational Research Review Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Honors & Awards
| 2023 | Robert A. Winn Excellence in Clinical Trials: Career Development Award, Robert A. Winn Foundation |
| 2022 - 2023 | ASCO Young Investigator Award, American Society of Clinical Oncology |
| 2022 - 2023 | ASH Minority Hematology Fellow Award, American Society of Hematology |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2013. Evaluation of different isoforms of PI3K as viable targets for therapy of HER2-positive breast cancer using a novel genetically engineered mouse (GEM) model. Conference. Evaluation of different isoforms of PI3K as viable targets for therapy of HER2-positive breast cancer using a novel genetically engineered mouse (GEM) model. Boston, MA, US.
- 2012. Understanding the molecular mechanism of cell pluripotency in C. elegan. Conference. Understanding the molecular mechanism of cell pluripotency in C. elegan. Santa Barbra, CA, US.
- 2011. Identifying the cells surface marker profile of Triple Negative breast cancer tumors. Conference. Identifying the cells surface marker profile of Triple Negative breast cancer tumors. Los Angeles, CA, US.
- 2010. Dissecting the transcription network of WNT10B/b-catenin signaling in triple negative breast cancer tumors. Conference. Dissecting the transcription network of WNT10B/b-catenin signaling in triple negative breast cancer tumors. Anaheim, CA, US.
- 2007. The effect of testosterone on glucose uptake in adipose cells. Conference. The effect of testosterone on glucose uptake in adipose cells. Los Angeles, CA, US.
National Presentations
- 2025. Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort. Poster. 67th ASH Meeting, US.
- 2025. Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium. Poster. 67th ASH Meeting, US.
- 2024. Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma. Poster. 66th ASH Meeting, US.
- 2024. Factors Influencing Clinical Trial Participation Among Patients with Non-Hodgkin Lymphoma Receiving Care in a Safety Net Hospital. Poster. 66th ASH Meeting, US.
- 2024. Real-World Outcomes in Patients With Burkitt Lymphoma in a Safety-Net Health System. Poster. NCCN 2024 Annual Conference, US.
- 2023. Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy-a Single-Institution Experience. Conference. 65th ASH Annual Meeting. San Diego, California, US.
- 2023. Perceptions and Practices of Clinical Trial Enrollment Among Patients with Non-Hodgkin Lymphoma, Caregivers, and Providers. Conference. 65th ASH Annual Meeting. San Diego, California, US.
- 2023. Clinical Outcomes of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in a County Hospital System. Conference. 65th ASH Annual Meeting. San Diego, California, US.
- 2022. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at A Major Academic Institution. Conference. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at A Major Academic Institution. New Orleans, LA, US.
Grant & Contract Support
| Date: | 2023 - 2030 |
| Title: | A Ph 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) + Rituximab or Obinutuzumab Vs Lenalidomide plus Rituximab in Pts w R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) |
| Funding Source: | BeiGene LTD |
| Role: | PI |
| ID: | AWD00007595 |
| Date: | 2023 - 2026 |
| Title: | Characteristics and Outcomes of Patients with Follicular Lymphoma with at least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers within the LEO Consortium |
| Funding Source: | Genentech, Inc |
| Role: | Co-PI |
| ID: | AWD00007910 |
| Date: | 2023 - 2026 |
| Title: | Comprehensive multicenter examination of barriers & facilitators of Lymphoma Clinical trial participation and evaluation of strategies to enhance participation amongst underrepresented patient groups |
| Funding Source: | Bristol Myers Squibb Foundation |
| Role: | PI |
| ID: | AWD00008022 |
| Date: | 2023 - 2026 |
| Title: | Real-Work Outcomes in Patients with Relapsed or Refractory Aggressive B-Cell Non- Hodgkin Lymphoma |
| Funding Source: | Genmab US, Inc |
| Role: | Co-PI |
| ID: | AWD00007709 |
| Date: | 2023 - 2026 |
| Title: | Characteristics and Outcomes of Patients with Follicular Lymphoma with at least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers within the LEO Consortium |
| Funding Source: | Genentech, Inc |
| Role: | Co-PI |
| ID: | AWD00007358 |
| Date: | 2023 - 2025 |
| Title: | Strategic Alliance Agreement : A Phase 1 Study of Valemetostat in combination with Rituximab and Lenalidomide in R/R Follicular Lymphoma |
| Funding Source: | Daiichi Sankyo., CO LTD |
| Role: | PI |
| ID: | 54920 |
| Date: | 2022 - 2025 |
| Title: | ASH Minority Hematology Fellow Award: Assessing barriers to enrollment of Minority patients in Therapeutic Lymphoma Clinical trials |
| Funding Source: | American Society of Hematology |
| Role: | PI |
| ID: | AWD00007104 |
| Date: | 2022 - 2029 |
| Title: | A Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide in Patients with Follicular Lymphoma after at least one line of systemic therapy |
| Funding Source: | Genentech, Inc |
| Role: | PI |
| ID: | AWD00006003 |
| Date: | 2021 - 2026 |
| Title: | The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study / Multiple Investigators/ renewal |
| Funding Source: | National Cancer Institute |
| Role: | Key |
| ID: | U01 CA195568-8 |
Selected Publications
Peer-Reviewed Articles
- Nguyen, TM, Lu, J, Guffey, D, Kim, RB, Oluyomi, AO, Rosales, O, Bandyo, R, Miller-Chism, CN, Udden, MM, Mims, MP, Abuasab, T, Diamond, A, Teegavarapu, PS, Nze, CC, Flowers, CR, Li, A, Jiang, JY. Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System. Clinical Lymphoma, Myeloma and Leukemia 26(1):e12-e20.e5, 2026. e-Pub 2026. PMID: 40946017.
- Atallah-Yunes SA, Nze C, King RL, Rees MJ, Alderuccio JP, Watkins M, Kahl BS, Easwar N, Yamshon S, Ravindra A, Farooq U, Rosenthal A, Munoz J, Rojas-Neira EM, Ayers AA, Muhamad, Moustafa A, Habermann TM, Witzig TE, Ansell SM, Nowakowski GS, Koff JL, Flowers CR, Wang Y. Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Clinical Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies. American Journal of Hematology 100(12):2185-2194, 2025. e-Pub 2025. PMID: 40899786.
- Jiang JY, Nguyen TM, Lu J, Guffey D, Kim R, Oluyomi AO, Rosales O, Bandyo R, Miller-Chism CN, Udden MM, Mims MP, Abuasab T, Diamond A, Teegavarapu PS, Nze CC, Flowers CR, Li A. Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System. Clinical Lymphoma, Myeloma and Leukemia. e-Pub 2025.
- Manzar, G, Pinnix, CC, Dudzinski, SO, Marqueen, KE, Cha, E, Nasr, L, Yoder, A, Rooney, MK, Strati, P, Ahmed, S, Nze, CC, Nair, R, Fayad, LE, Wang, L, Nastoupil, L, Westin, JR, Flowers, CR, Neelapu, SS, Gunther, J, Dabaja, BS, Wu, SY, Fang, PQ. Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 39958356.
- Nze C, Herrera AF. New Strategies for Enhancing Enrollment of Underrepresented Minorites in Lymphoma Clinical Trials. Blood Adv 9(4):774-782, 2024. e-Pub 2024. PMID: 39631075.
- Fang, PQ, Noticewala, SS, Wu, SY, Gunther, J, Ludmir, EB, Medeiros, LJ, Strati, P, Nair, R, Nze, CC, Nastoupil, L, Ahmed, S, Castillo, LM, Fayad, LE, Westin, J, Neelapu, SS, Flowers, CR, Huen, A, Iyer, SP, Dabaja, BS, Pinnix, CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type. Advances in Radiation Oncology 9(12), 2024. e-Pub 2024. PMID: 39553398.
- Jiang, JY, Nze, CC, Guffey, D, Kim, RB, Oluyomi, AO, Rosales, O, Bandyo, R, Miller-Chism, CN, Udden, MM, Mims, MP, Ma, HY, Rivero, GA, Diamond, A, Teegavarapu, PS, Li, A, Flowers, CR. Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system. Blood Neoplasia 1(3), 2024. e-Pub 2024. PMID: 40453060.
- Nze C, Andersen CR, Ayers AA, Westin J, Wang M, S Iyer, Ahmed S, Pinnix, Vega, Nguyen L, Nastoupil LJ, Zhang K, Bauer CX, Flowers CR. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma. Blood Advances, 2024. e-Pub 2024. PMID: 38607394.
- Nze C, Andersen CR, Ayers AA, Westin J, Wang M, Iyer S, Ahmed S, Pinnix C, Vega F, Nguyen L, McNeill L, Nastoupil LJ, Zhang K, Bauer CX, Flowers CR. Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL. Blood Adv 8(14):3825-3837, 2024. e-Pub 2024. PMID: 38607394.
- Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
- Nze, CC, Msaouel, P, Derbala, M, Stephen, B, Abonofal, A, Meric-Bernstam, F, Tannir, NM, Naing, A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers 15(15), 2023. e-Pub 2023. PMID: 37568622.
- Li A, De Las Pozas G, Andersen CR, Nze CC, Toale KM, Milner EM, Fillmore NR, Chiao EY, Rojas Hernandez C, Kroll MH, Merriman KW, Flowers CR. External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center. Am J Hematol 98(7):1052-1057, 2023. e-Pub 2023. PMID: 37067102.
- Nwanaji-Enwerem JC, Nze C, Cardenas A. Long-term Aspirin Use and Epigenetic Mitotic Clocks for Cancer Risk Prediction: Findings in Healthy Colon Mucosa and Recommendations for Future Epigenetic Aging Studies. Epigenetics Commun 1(1), 2021. e-Pub 2021. PMID: 35493198.
- Nze C, Fortin B, Freedman R, Mandell E, Puligandla M, Neuberg D, Achebe M. Sudden death in sickle cell disease: current experience. Br J Haematol 188(4):e43-e45, 2020. e-Pub 2020. PMID: 31804704.
- Eberly LA, Richterman A, Beckett AG, Wispelwey B, Marsh RH, Cleveland Manchanda EC, Chang CY, Glynn RJ, Brooks KC, Boxer R, Kakoza R, Goldsmith J, Loscalzo J, Morse M, Lewis EF, Abel S, Adams A, Anaya J, Andrews EH, Atkinson B, Avutu V, Bachorik A, Badri O, Bailey M, Baird K, Bakshi S, Balaban D, Barshop K, Baumrin E, Bayomy O, Beamesderfer J, Becker N, Berg DD, Berman AN, Blum SM, Boardman AP, Boden K, Bonacci RA, Brown S, Campbell K, Case S, Cetrone E, Charrow A, Chiang D, Clark D, Cohen AJ, Cooper A, Cordova T, Cuneo CN, de Feria AA, Deffenbacher K, DeFilippis EM, DeGregorio G, Deutsch AJ, Diephuis B, Divakaran S, Dorschner P, Downing N, Drescher C, D'Silva KM, Dunbar P, Duong D, Earp S, Eckhardt C, Elman SA, England R, Everett K, Fedotova N, Feingold-Link T, Ferreira M, Fisher H, Foo P, Foote M, Franco I, Gilliland T, Greb J, Greco K, Grewal S, Grin B, Growdon ME, Guercio B, Hahn CK, Hasselfeld B, Haydu EJ, Hermes Z, Hildick-Smith G, Holcomb Z, Holroyd K, Horton L, Huang G, Jablonski S, Jacobs D, Jain N, Japa S, Joseph R, Kalashnikova M, Kalwani N, Kang D, Karan A, Katz JT, Kellner D, Kidia K, Kim JH, Knowles SM, Kolbe L, Kore I, Koullias Y, Kuye I, Lang J, Lawlor M, Lechner MG, Lee K, Lee S, Lee Z, Limaye N, Lin-Beckford S, Lipsyc M, Little J, Loewenthal J, Logaraj R, Lopez DM, Loriaux D, Lu Y, Ma K, Marukian N, Matias W, Mayers JR, McConnell I, McLaughlin M, Meade C, Meador C, Mehta A, Messenger E, Michaelidis C, Mirsky J, Mitten E, Mueller A, Mullur J, Munir A, Murphy E, Nagami E, Natarajan A, Nsahlai M, Nze C, Okwara N, Olds P, Paez R, Pardo M, Patel S, Petersen A, Phelan L, Pimenta E, Pipilas D, Plovanich M, Pong D, Powers BW, Rao A, Ramirez Batlle H, Ramsis M, Reichardt A, Reiger S, Rengarajan M, Rico S, Rome BN, Rosales R, Rotenstein L, Roy A, Royston S, Rozansky H, Rudder M, Ryan CE, Salgado S, Sanchez P, Schulte J, Sekar A, Semenkovich N, Shannon E, Shaw N, Shorten AB, Shrauner W, Sinnenberg L, Smithy JW, Snyder G, Sreekrishnan A, Stabenau H, Stavrou E. Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. Circ Heart Fail 12(11):e006214, 2019. e-Pub 2019. PMID: 31658831.
- Green AR, Rosu C, Kenison T, Nze C. Assessing the hidden curriculum for the care of patients with limited english proficiency: An instrument development. Educ Health (Abingdon) 31(1):17-24, 2018. e-Pub 2018. PMID: 30117468.
- Green AR, Nze C. Language-Based Inequity in Health Care: Who Is the "Poor Historian"?. AMA J Ethics 19(3):263-271, 2017. e-Pub 2017. PMID: 28323607.
Review Articles
- Jiang, JY, Li, A, Romero, A, Flowers, CR, Nze, CC. Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials. Oncologist 30(6), 2025. e-Pub 2025. PMID: 40554671.
- Flowers CR, Anantha RW, Leautaud V, Desai P, Donald CE, Hildebrandt MAT, Koff JL, Tamimi RM, Cozen W, Nze C, Melnick AM. Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach. Blood Cancer Discov 6(2):79-93, 2025. e-Pub 2025. PMID: 39898759.
Editorials
- Nze C, Flowers. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program 2023(1):382-385, 2023. PMID: 38066850.
- Nze, Nastoupil LJ. CAR T-cell Therapy: A Major Shift in the Treatment Landscape for Early-Relapse Aggressive B-Cell Lymphomas. The Hematologist 20(1), 2023.
- Nze C. The Impact of Race on Mortality and Relapse in TTP. Practice update, 2022.
- Nze C, Flowers CR. Analyzing Racial and Ethnic Disparities in Multiple Myeloma FDA Drug Approval Trials. Practice update, 2022.
- Nze C. Association of Race/Ethnicity and Anticoagulation in Patients With Atrial Fibrillation Enrolled in VA and Medicare. Practice update, 2022.
- Nze C, Flowers CR. Potential Impact of Nurse Navigation Program in Achieving Equitable Care and Outcomes in Patients With Aggressive Large B-Cell Lymphoma. ASCO Post, 2021.
- Nze C. Socioeconomic Status and Suboptimal Iron Deficiency Screening in Pregnancy. Practice update, 2021.
- Nze C. Eliminating Race-Based Reference Ranges in Hematology. Practice update, 2021.
- Nze C, Avakame E, Ayankola J. Police brutality is our lane too, doctors say. STAT, 2020.
Abstracts
- Jiang JY, Nze C, Guffey D, Kim R, Ouyomi AO, Rosales O, Bandyo R, Diamond A, Rivero GA, Miller-Chism CN, Udden MM, Mims MP, Flowers CR, Li A, Teegavarapu PS. Clinical Outcomes of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in a County Hospital System. Blood 142(1):5140, 2023. e-Pub 2023.
- Graham T, Ackbarali T, Nze C, Bryant A, Duque AD, Flowers CR. Perceptions and Practices of Clinical Trial Enrollment Among Patients with Non-Hodgkin Lymphoma, Caregivers, and Providers. Blood 142(1):2388, 2023. e-Pub 2023.
- Nair R, Ogundipe I, Gunther J, Medeiros L, Jain P, Nastoupil LJ, Pinnix CC, Malpica L, Ahmed S, Miranda R, Fayad L, Steiner RE, Hagemeister F, Lee HJ, Rodriguez MA, Strati P, Chihara D, Wang M, Nieto Y, Ramdial J, Zaki AA, Nze C, Green MR, Dabaja BS, Xu J, Thakral B, Neelapu SS, Vega F, Flowers CR, Fang P, Westin J, Feng L, Iyer SP. Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience. Blood 142(1):6327, 2023. e-Pub 2023.
- Nze C, Andersen CR, Ayers A, Westin J, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, McNeil L, Nguyen L, Nastoupil LJ, Flowers CR. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution. Blood 140(1):7943–7945, 2022. e-Pub 2022.
- Nze C, Fortin BM, Freedman R, Puligandla M, MS, Neuberg DS, ScD, Mandell E, ANP, Achebe M, MD MPH. Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors. Blood, 2018. e-Pub 2018.
- Nze C, Jiang JY, Nze C, Guffey D, O Ouyomi RKA, Rosales O, Bandyo R, Diamond A, Rivero GA, Miller-Chism CN, Udden MM, Mims MP, Flowers CR, Li A, Teegavarapu PS. Clinical Outcomes of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma in a County Hospital System. American Society of Hematology Annual conference.
- Graham T, Ackbarali T, Nze C, Bryant A, Duque AD, Flowers CR. Perceptions and Practices of Clinical Trial Enrollment Among Patients with Non-Hodgkin Lymphoma, Caregivers, and Providers.
Patient Reviews
CV information above last modified July 22, 2026